NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model

Core Insights - NurExone Biologic Inc. announced promising preclinical results for its lead candidate ExoPTEN, demonstrating a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma [1][2] - The study, conducted in collaboration with the Goldschleger Eye Institute, showed that higher doses of ExoPTEN lead to measurable recovery of visual function in animals with optic nerve injury [2][3] - The company is accelerating the expiration of certain warrants, which could yield approximately C$3.2 million if exercised, to support corporate and working capital needs [11][12] Company Developments - ExoPTEN has shown a clear, dose-dependent effect in improving visual signal strength, with high-dose groups achieving response amplitudes comparable to uninjured eyes [5][7] - The optic nerve crush model used in the study mimics damage seen in glaucoma, a leading cause of irreversible blindness [4] - The collaboration with Prof. Ygal Rotenstreich's team is expected to open new treatment avenues for blinding glaucoma and other ophthalmological conditions [6] Financial and Strategic Moves - The company is accelerating the expiration of 2,515,456 September 2023 Warrants and 5,653,073 January 2024 Warrants due to meeting specific trading price thresholds [11][13] - The warrants will now expire on November 7, 2025, and approximately 89% are held by U.S.-based investors [15][14] - The agreement with POSITIVE Communications has been extended to July 10, 2026, with additional financial terms [16][17] Research and Development - The dose-response study is the third independent investigation of ExoPTEN's activity, complementing previous results that showed structural preservation of retinal ganglion cells [3][4] - The findings support the potential of ExoPTEN as a therapeutic option for patients with optic nerve damage, advancing towards future clinical trials [3][18] - NurExone is focused on developing regenerative therapies for central nervous system injuries, with ExoPTEN targeting multi-billion-dollar markets [18]